IL225966A0 - Preparations for the treatment of respiratory arrest following an opioid overdose - Google Patents

Preparations for the treatment of respiratory arrest following an opioid overdose

Info

Publication number
IL225966A0
IL225966A0 IL225966A IL22596613A IL225966A0 IL 225966 A0 IL225966 A0 IL 225966A0 IL 225966 A IL225966 A IL 225966A IL 22596613 A IL22596613 A IL 22596613A IL 225966 A0 IL225966 A0 IL 225966A0
Authority
IL
Israel
Prior art keywords
formulations
methods
respiratory depression
opioid overdose
depression induced
Prior art date
Application number
IL225966A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alpharma Pharmaceuticals Llc
Michael J Lamson
Veeraindar Goli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals Llc, Michael J Lamson, Veeraindar Goli filed Critical Alpharma Pharmaceuticals Llc
Publication of IL225966A0 publication Critical patent/IL225966A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL225966A 2010-10-26 2013-04-25 Preparations for the treatment of respiratory arrest following an opioid overdose IL225966A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
IL225966A0 true IL225966A0 (en) 2013-06-27

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225966A IL225966A0 (en) 2010-10-26 2013-04-25 Preparations for the treatment of respiratory arrest following an opioid overdose

Country Status (14)

Country Link
US (3) US20140030343A1 (enExample)
EP (1) EP2632442A2 (enExample)
JP (1) JP2013540807A (enExample)
KR (3) KR20160017668A (enExample)
CN (1) CN103189055A (enExample)
AU (1) AU2011322147A1 (enExample)
BR (1) BR112013009267A2 (enExample)
CA (1) CA2814230A1 (enExample)
IL (1) IL225966A0 (enExample)
MX (1) MX2013003832A (enExample)
RU (1) RU2541159C2 (enExample)
SG (1) SG189234A1 (enExample)
WO (1) WO2012056402A2 (enExample)
ZA (1) ZA201302363B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
EP2670400A1 (en) * 2011-02-02 2013-12-11 Alpharma Pharmaceuticals LLC Pharmaceutical composition comprising opioid agonist and sequestered antagonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
IL273627B2 (en) 2017-12-20 2025-03-01 Purdue Pharma Lp Morphine sulfate dosage forms for abuse deterrence
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023081185A1 (en) * 2021-11-02 2023-05-11 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
CN1901954B (zh) * 2003-12-05 2013-01-16 康尔福盛303有限公司 借助病人监测系统的病人自控镇痛技术
CN101321686A (zh) 2005-10-07 2008-12-10 佛罗里达大学研究基金会有限公司 用于多路信号传递和光编码的多组分纳米颗粒
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2008296905A1 (en) * 2007-09-04 2009-03-12 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
BRPI0911715A2 (pt) 2008-07-31 2019-09-24 Alma Mater Studiorum - Universita' Di Bologna partículas ativas para aplicações bio-analíticas e métodos para sua preparação.
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Also Published As

Publication number Publication date
CA2814230A1 (en) 2012-05-03
KR20170102571A (ko) 2017-09-11
WO2012056402A3 (en) 2012-10-04
US20140030343A1 (en) 2014-01-30
ZA201302363B (en) 2014-06-25
JP2013540807A (ja) 2013-11-07
CN103189055A (zh) 2013-07-03
US20160045449A1 (en) 2016-02-18
KR20160017668A (ko) 2016-02-16
SG189234A1 (en) 2013-05-31
RU2013117274A (ru) 2014-12-10
KR20130097211A (ko) 2013-09-02
US20170367987A1 (en) 2017-12-28
BR112013009267A2 (pt) 2016-07-26
RU2541159C2 (ru) 2015-02-10
WO2012056402A2 (en) 2012-05-03
AU2011322147A1 (en) 2013-04-18
MX2013003832A (es) 2013-10-01
EP2632442A2 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
IL225966A0 (en) Preparations for the treatment of respiratory arrest following an opioid overdose
ZA201401526B (en) Method and formulation for inhalation
EP2521584A4 (en) INHALATION DEVICE AND METHOD THEREFOR
IL237258A0 (en) Methods for treating or preventing asthma by administering an antagonist to -il-r4
IL223118A (en) Inhaler of cure and method for its composition
ZA201304406B (en) Inhalator
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
AU336564S (en) Respiratory mask
EP2621588A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
HUE040353T2 (hu) Inhalátorból és kapszulából álló rendszer
IL221768A (en) From women
EP2741665A4 (en) SEQUENCING EVENTS USING ACOUSTIC RESPIRATORY MARKERS AND ASSOCIATED METHODS
GB201200525D0 (en) An inhalable medicament
IL271284A (en) Methods for treating or preventing asthma by administering an antagonist to -il-r4
AU2011903839A0 (en) Inhalation device and method
HK1192508A (en) Systems and methods for administering an exercise program
AU333535S (en) Respiratory device
GB201007724D0 (en) Respiratory therapy apparatus
AU2011905457A0 (en) Respiratory physiotherapy device
GB201012660D0 (en) Inhaler and formulation
AU2011903049A0 (en) Method and formulation for inhalation